UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16or 15d-16

Under the Securities Exchange Act of 1934

For the Month of August 2025

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)

NeuroSense Therapeutics Ltd.

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9- 7996183
(Address of principal executive offices)

Indicate by check mark whether the registrant filesor will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

As of August 20, 2025, approximately 20% of people with ALS from theCompany’s Phase 2a study -  including those continuing under compassionate use - remain on PrimeC for more than 5.5 years,having lived with ALS for over 7 years. Across these multi-year exposures, treatment remains well tolerated, with no new safety signalsobserved to date.

ThisReport on Form 6-K (other than the third paragraph of Exhibit 99.1) is hereby incorporated by reference into registrant’s RegistrationStatements on Form S-8 (FileNo. 333-262480) and Form F-3 (File No. 333-269306, 333-260338, 333-283656 and 333-284051),to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequentlyfiled or furnished.

SIGNATURES

Pursuant to the requirementsof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereuntoduly authorized.